A complete line of products

Fidia’s target in each therapeutic area is to provide not just one but a complete line of products for the treatment of conditions at all stages of their evolution.

Fidia plans to achieve this through research, completing its strategic programme with industrial projects for the production and marketing of generics.

Generics are an indispensable part of Fidia’s development strategy, because in choosing the drugs to place on the market, the current need to reduce health expenditure must be a prime consideration. Consequently, generics now represent one of the company’s strategic assets.